Becton Dickinson Reports Strong Start to Fiscal 2024 with Revenue and EPS Growth
The medical technology company's strategic focus on innovation and growth sectors has led to a 7% revenue increase and an EPS that surpassed forecasts.
- Becton Dickinson's Q1 earnings exceeded market expectations with a 7% revenue increase and an adjusted EPS of $2.68, beating the consensus of $2.40.
- The company's strategic emphasis on areas like connected care and chronic disease management has fueled its growth, despite a slight dip in Life Sciences revenue.
- BD has raised its revenue and EPS guidance for fiscal 2024, reflecting confidence in its ongoing strategic initiatives.
- The company's financial health is robust, with a market cap of $69.96 billion and a gross profit margin of 44.72% over the last twelve months as of Q1 2024.
- BD's stock offers a potential investment opportunity, trading near its 52-week low but with promising growth prospects and a history of 53 consecutive years of dividend growth.
BNN Breaking 
Benzinga 
